• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sanofi-Aventis S.A. ADR (NQ: SNY )

    51.13 +0.51 (+1.01%)
    Streaming Delayed Price Updated: 12:41 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,110,150
    Open 50.97
    Bid (Size) 51.12 (6)
    Ask (Size) 51.13 (3)
    Prev. Close 50.62
    Today's Range 50.87 - 51.27
    52wk Range 42.63 - 55.72
    Shares Outstanding 1,250,690,553
    Dividend Yield 3.72%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
    The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season. 
    Via Benzinga
    European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
    European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
    Via Benzinga
    Exposures COVID-19

    Performance

    YTD
    +2.26%
    +2.26%
    1 Month
    +8.30%
    +8.30%
    3 Month
    +8.44%
    +8.44%
    6 Month
    +0.59%
    +0.59%
    1 Year
    -5.17%
    -5.17%

    More News

    Read More
    Stable Blue-Chip Stocks to Buy Before Earnings Season
    Via InvestorPlace
    Senate To Review Novo Nordisk's Levemir Insulin Discontinuation
    Via Benzinga
    Sanofi's $20B Consumer Health Unit Sale: Goldman Sachs, Morgan Stanley Line Up $6.5B Financing
    Via Benzinga
    Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
    Via Benzinga
    EXCLUSIVE: VeeCon 2024 Announces Danica Patrick, Jerome Bettis, Paul Scheer, Mike Posner, Liquid Death CEO Mike Cessario As New Speakers
    Via Benzinga
    3 Stocks to Sell Immediately Based on the French Election Results
    Via InvestorPlace
    What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
    Via Investor's Business Daily
    Upcoming Stock Spinoffs: Should You Pounce or Pass?
    Via InvestorPlace
    7 Safe Haven Stocks to Buy Before the Next Market Correction
    Via InvestorPlace
    Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
    Via Benzinga
    Exposures Product Safety
    Novavax’s Second Act: How a Fallen COVID Star Could Rise from the Ashes
    Via InvestorPlace
    Exposures COVID-19
    Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
    Via Benzinga
    Where Will Novavax Be in 1 Year?
    Via The Motley Fool
    First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
    Via Benzinga
    Exposures Product Safety
    Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
    Via InvestorPlace
    Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
    Via Benzinga
    Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Is It Too Late to Buy Novavax Stock?
    Via The Motley Fool
    Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
    Via Investor's Business Daily
    Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
    Via Investor's Business Daily
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.